Skip to main content
. 2015 Jun 22;290(36):22030–22048. doi: 10.1074/jbc.M115.662791

FIGURE 4.

FIGURE 4.

Assessing the neuroprotective properties of the PSD-95/PDZ-binding peptidomimetic compounds against NMDA-induced LPMS in the retina. Representative flat mount views of the GCL were taken from an area 1–2 mm from the optic nerve head 4 h following NMDA insult. a, retinas exposed to NMDA alone (n = 5) displayed a densely labeled distribution of EtBr-positive cells. b, retinas exposed to the PSD/PDZ domain-binding peptide CN2097 (n = 4) fully attenuated NMDA-induced LPMS. c, PSD-95-interacting peptide Tat-NR2B9c (n = 4) was also shown to reduce but not fully attenuate NMDA-induced LPMS. The non-PDZ-binding cyclic controls containing the polyarginine uptake carrier CN5125 (n = 4) (d) and CN5135 (n = 3) (e) both fully attenuated NMDA-induced LPMS. f, CN2180 (n = 3), a myristoyl-linked PSD-95-binding cyclic peptide, did not block LPMS. g, no cell staining was detected in the untreated retina (n = 5). h, histogram displaying the average labeling distributions from the sample areas above. Error bars S.E. *, treatment condition is significantly different from NMDA alone, p < 0.0001.